Prognosis
CureVac Coronavirus Vaccine Cleared for Human Trials in Germany
- State-backed CureVac wins approval to test its product
- Vaccine teaches body’s cells to identify and attack the virus
This article is for subscribers only.
Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news and analysis.
Germany’s CureVac AG won approval to start human trials of a novel coronavirus vaccine just days after the company secured backing from Chancellor Angela Merkel’s government.